Beijing HuiNengAn Biotech

Beijing HuiNengAn Biotech is a biotechnology company specializing in the development of innovative gene therapies for central nervous system (CNS) and metabolic disorders. The company utilizes a proprietary adeno-associated virus (AAV) vector platform designed to efficiently deliver therapeutic genes across the blood-brain barrier. Its lead program, HNA-001, is a gene therapy candidate targeting Parkinson's disease associated with GBA1 mutations, aiming to restore enzyme activity and reduce neurodegeneration. Founded in 2021 by industry veterans with experience at Biogen and Sanofi, the company is focused on creating one-time curative treatments for both rare and common genetic conditions. HuiNengAn is headquartered in Beijing and has secured significant funding from leading venture capital firms to advance its pre-clinical pipeline toward human trials.